• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Director Pyle Margaret B was granted 1,896 shares (SEC Form 4)

    5/9/25 1:33:49 PM ET
    $KEQU
    Medical Specialities
    Industrials
    Get the next $KEQU alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    PYLE MARGARET B

    (Last) (First) (Middle)
    2700 WEST FRONT STREET

    (Street)
    STATESVILLE NC 28677

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    KEWAUNEE SCIENTIFIC CORP /DE/ [ KEQU ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/07/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/07/2025 A 1,896 A $0(1) 1,896 D
    Common Stock 5,000 I By Spouse(2)
    Common Stock 38,070 I By Trust(2)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Shares awarded under the Company's 2023 Omnibus Incentive Plan, representing the equity portion of the reporting person's annual director compensation.
    2. The reporting person disclaims beneficial ownership of these shares.
    Remarks:
    /s/ Donald T. Gardner III, Attorney-in-fact 05/09/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $KEQU alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KEQU

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KEQU
    SEC Filings

    See more
    • SEC Form SD filed by Kewaunee Scientific Corporation

      SD - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Filer)

      5/9/25 10:54:08 AM ET
      $KEQU
      Medical Specialities
      Industrials
    • SEC Form 144 filed by Kewaunee Scientific Corporation

      144 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Subject)

      3/31/25 4:23:01 PM ET
      $KEQU
      Medical Specialities
      Industrials
    • SEC Form 10-Q filed by Kewaunee Scientific Corporation

      10-Q - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Filer)

      3/14/25 10:22:53 AM ET
      $KEQU
      Medical Specialities
      Industrials

    $KEQU
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kewaunee Scientific Announces Amendment to Share Repurchase Program

      STATESVILLE, N.C., March 12, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced an amendment to its existing share repurchase program. On March 12, 2025, the Board of Directors of Kewaunee Scientific Corporation (the "Company") amended its existing share repurchase program initially approved on August 31, 2023, and in effect September 1, 2023. The Board of Directors authorized the repurchase of up to an additional 100,000 shares of the Company's common stock under the existing share repurchase program, as amended (the "Program"), which does not

      3/12/25 5:08:00 PM ET
      $KEQU
      Medical Specialities
      Industrials
    • Kewaunee Scientific Reports Results for Third Quarter of Fiscal Year 2025

      STATESVILLE, N.C., March 12, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its third quarter ended January 31, 2025. Fiscal Year 2025 Third Quarter Results: Sales during the third quarter of fiscal year 2025 were $67,167,000, an increase of 43.6% compared to sales of $46,778,000 from the prior year's third quarter. Pre-tax earnings for the quarter were $1,275,000 compared to $3,515,000 for the prior year quarter, a decrease of 63.7%. Net earnings were $1,354,000 compared to net earnings of $2,521,000 for the prior year quarter.

      3/12/25 4:16:00 PM ET
      $KEQU
      Medical Specialities
      Industrials
    • Kewaunee Scientific to Report Results for Third Quarter Fiscal Year 2025

      STATESVILLE, N.C., Feb. 26, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced that the Company plans to release its third quarter fiscal year 2025 financial results on Wednesday, March 12, 2025 after the close of trading. This information will be available on the Company's website www.kewaunee.com after the release. About Kewaunee Scientific Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. The Company's produc

      2/26/25 5:21:00 PM ET
      $KEQU
      Medical Specialities
      Industrials

    $KEQU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Gehl Keith M bought $35,000 worth of shares (1,000 units at $35.00), increasing direct ownership by 6% to 18,500 units (SEC Form 4)

      4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

      4/7/25 10:57:11 AM ET
      $KEQU
      Medical Specialities
      Industrials
    • Director Gehl Keith M bought $22,500 worth of shares (500 units at $45.00), increasing direct ownership by 3% to 17,500 units (SEC Form 4)

      4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

      3/24/25 4:32:54 PM ET
      $KEQU
      Medical Specialities
      Industrials
    • Director Gehl Keith M bought $19,747 worth of shares (403 units at $49.00), increasing direct ownership by 2% to 17,000 units (SEC Form 4)

      4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

      3/18/25 3:20:26 PM ET
      $KEQU
      Medical Specialities
      Industrials

    $KEQU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Kewaunee Scientific Corporation

      SC 13G/A - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Subject)

      11/1/24 9:14:13 AM ET
      $KEQU
      Medical Specialities
      Industrials
    • SEC Form SC 13G/A filed by Kewaunee Scientific Corporation (Amendment)

      SC 13G/A - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Subject)

      2/9/24 11:44:29 AM ET
      $KEQU
      Medical Specialities
      Industrials
    • SEC Form SC 13G/A filed by Kewaunee Scientific Corporation (Amendment)

      SC 13G/A - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Subject)

      2/9/24 9:59:14 AM ET
      $KEQU
      Medical Specialities
      Industrials

    $KEQU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Pyle Margaret B was granted 1,896 shares (SEC Form 4)

      4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

      5/9/25 1:33:49 PM ET
      $KEQU
      Medical Specialities
      Industrials
    • Director Russell John was granted 1,896 shares, increasing direct ownership by 6% to 34,396 units (SEC Form 4)

      4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

      5/9/25 10:58:43 AM ET
      $KEQU
      Medical Specialities
      Industrials
    • Director Gehl Keith M was granted 1,896 shares, increasing direct ownership by 10% to 20,396 units (SEC Form 4)

      4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

      5/9/25 10:56:19 AM ET
      $KEQU
      Medical Specialities
      Industrials

    $KEQU
    Financials

    Live finance-specific insights

    See more
    • Kewaunee Scientific Reports Results for Third Quarter of Fiscal Year 2025

      STATESVILLE, N.C., March 12, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its third quarter ended January 31, 2025. Fiscal Year 2025 Third Quarter Results: Sales during the third quarter of fiscal year 2025 were $67,167,000, an increase of 43.6% compared to sales of $46,778,000 from the prior year's third quarter. Pre-tax earnings for the quarter were $1,275,000 compared to $3,515,000 for the prior year quarter, a decrease of 63.7%. Net earnings were $1,354,000 compared to net earnings of $2,521,000 for the prior year quarter.

      3/12/25 4:16:00 PM ET
      $KEQU
      Medical Specialities
      Industrials
    • Kewaunee Scientific Reports Results for Second Quarter of Fiscal Year 2025

      STATESVILLE, N.C., Dec. 11, 2024 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its second quarter ended October 31, 2024. Fiscal Year 2025 Second Quarter Results: Sales during the second quarter of fiscal year 2025 were $47,764,000, a decrease of 5.3% compared to sales of $50,436,000 from the prior year's second quarter. Pre-tax earnings for the quarter were $3,931,000 compared to $4,845,000 for the prior year quarter, a decrease of 18.9%. Net earnings were $3,008,000 compared to net earnings of $2,732,000 for the prior year quarter.

      12/11/24 4:04:00 PM ET
      $KEQU
      Medical Specialities
      Industrials